In addition, the intraperitoneal (ip) administration of immunostimulatory TLR9-agonist DNA sequences protects mice from DSS-induced colitis via the induction of indoleamine 2,3 dioxygenase-1 [176,177]. This evidence concerns the gene TLR9 and colitis.